 STAMFORD, Conn., Aug. 03, 2020 GLOBE NEWSWIRE -- Cara Therapeutics, Inc. Nasdaq:CARA, a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020, at 4:30 p.m. ET to report second quarter 2020 financial results and provide a corporate update. To participate in the conference call, please dial 855 445-2816 domestic or 484 756-4300 international and refer to conference ID 7669087. A live webcast of the call can be accessed under Events Presentations in the News Investors section of the Companys website at archived webcast recording will be available on the Cara website beginning approximately two hours after the call.About Cara TherapeuticsCara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVATM CR845difelikefalin, a first-in-class KOR agonist that targets the bodys peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus CKD-aP. Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.The FDA has conditionally accepted KORSUVATM as the trade name for difelikefalin injection. CR845difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 CONTACT: Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 